Aromatase Inhibition in Advanced Prostatic Cancer
Author Information
Author(s): J.H. Davies, M. Dowsett, S. Jacobs, R.C. Coombes, A. Hedley, R.J. Shearer
Primary Institution: St Georges Hospital and Royal Marsden Hospital, London
Hypothesis
Can the steroidal aromatase inhibitor 4-hydroxyandrostenedione (4-OHA) effectively manage advanced hormone-resistant prostatic cancer?
Conclusion
4-OHA was found to be effective in providing symptom relief for patients with advanced prostate cancer who had failed other treatments.
Supporting Evidence
- Eighteen of 25 patients (72%) showed a subjective response, mainly in the form of pain relief.
- A tumour flare occurred in 17/25 (68%) of patients.
- Suppression of serum oestradiol levels occurred in 19/25 (76%) of patients during treatment with 4-OHA.
Takeaway
Doctors tested a medicine called 4-OHA to help men with a tough kind of prostate cancer, and many felt better, especially with their pain.
Methodology
The study involved 30 patients with advanced prostatic cancer, assessing their responses to 4-OHA through clinical and endocrine evaluations.
Potential Biases
Potential bias due to the subjective nature of patient-reported outcomes.
Limitations
The study had a small sample size and lacked objective improvements in tumor size.
Participant Demographics
Patients were aged 59-87 years, with a majority having undergone orchidectomy and experiencing severe bone pain from metastases.
Statistical Information
P-Value
p<0.001
Statistical Significance
p<0.001
Want to read the original?
Access the complete publication on the publisher's website